Intellia Therapeutics, Inc. (NTLA) vs Vir Biotechnology, Inc. (VIR)
Intellia Therapeutics, Inc. and Vir Biotechnology, Inc. are both Biotechnology companies. Intellia Therapeutics, Inc. and Vir Biotechnology, Inc. are of similar size ($1.8B and $1.7B). Vir Biotechnology, Inc. grew revenue faster over the last twelve months: 1,495.9% against 12.6%. Vir Biotechnology, Inc. has the higher net margin (−83.0% vs −672.2%) and the higher return on invested capital (−39.1% vs −91.3%). Across the 16 metrics below, Vir Biotechnology, Inc. leads on 13 and Intellia Therapeutics, Inc. on 3.
Valuation
Profitability
| Metric | NTLA | VIR | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 65.16% |
| Operating margin | (711.66%) | (92.40%) | 0.00% |
| Net margin | (672.16%) | (83.00%) | 0.00% |
| Free cash flow margin | (585.82%) | (67.17%) | 0.00% |
| Return on equity | (55.44%) | (26.08%) | (57.72%) |
| Return on assets | (45.55%) | (20.91%) | (49.22%) |
| Return on invested capital | (91.28%) | (39.10%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack